Chung-Han Lee, Ph.D.
Affiliations: | 2009 | University of Michigan, Ann Arbor, Ann Arbor, MI |
Area:
Molecular BiologyGoogle:
"Chung-Han Lee"Mean distance: 30533.1
Parents
Sign in to add mentorKunliang Guan | grad student | 2009 | University of Michigan | |
(Glucose starvation induces apoptosis of TSC-/- cells in a p53-dependent manner.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Reese SW, Eismann L, White C, et al. (2023) Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinoma. Urologic Oncology |
Kotecha RR, Doshi SD, Knezevic A, et al. (2023) A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer. European Urology Oncology |
Albiges L, Gurney H, Atduev V, et al. (2023) Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. The Lancet. Oncology |
Hahn AW, Kotecha RR, Viscuse PV, et al. (2023) Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. European Urology Focus |
McGregor B, Geynisman DM, Burotto M, et al. (2023) A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma. European Urology Oncology |
Fitzgerald KN, Motzer RJ, Lee CH. (2022) Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascade. Nature Reviews. Urology |
Fitzgerald KN, Duzgol C, Knezevic A, et al. (2022) Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations. European Urology |
Ged Y, Lee CH. (2022) Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma. Expert Review of Anticancer Therapy. 22: 1049-1059 |
Tourigny DS, Zucker M, Kim M, et al. (2022) Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma. Frontiers in Oncology. 12: 910147 |
Kotecha RR, Gedvilaite E, Ptashkin R, et al. (2022) Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma. Jco Precision Oncology. 6: e2200012 |